Kilitch Drugs (India) Limited Total Liabilities
Kilitch Drugs (India) Limited total liabilities. Based on the latest financial reports, Kilitch Drugs (India) Limited (KILITCH) has total liabilities worth Rs1.34 Billion INR (≈ $14.54 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Kilitch Drugs (India) Limited (KILITCH) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kilitch Drugs (India) Limited (2006–2025)
Total liabilities of Kilitch Drugs (India) Limited from 2006 to 2025. This chart illustrates how Kilitch Drugs (India) Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Kilitch Drugs (India) Limited (KILITCH) long-term investment share to see how much of total assets are deployed in long-term investments.
Kilitch Drugs (India) Limited Competitors by Total Liabilities
The table below lists competitors of Kilitch Drugs (India) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NET Power Inc.
NYSE:NPWR
|
USA | $24.95 Million |
|
Resource Mining Corporation Ltd
AU:RMI
|
Australia | AU$586.09K |
|
Pulmonx Corp
NASDAQ:LUNG
|
USA | $75.54 Million |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
India | Rs-3.00 Billion |
|
Chunghwa Chemical Synthesis & Biotech Co Ltd
TW:1762
|
Taiwan | NT$1.28 Billion |
|
Gowing Bros Ltd
AU:GOW
|
Australia | AU$132.17 Million |
|
Hitech Corporation Limited
NSE:HITECHCORP
|
India | Rs1.95 Billion |
|
Formosa Prosonic Industries
KLSE:9172
|
Malaysia | RM102.68 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Kilitch Drugs (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Kilitch Drugs (India) Limited.
Liquidity & Leverage Metrics
Kilitch Drugs (India) Limited Total Liabilities Ratios Explained
Kilitch Drugs (India) Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.40 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kilitch Drugs (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kilitch Drugs (India) Limited (2006–2025)
The table below shows the annual total liabilities of Kilitch Drugs (India) Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs1.12 Billion ≈ $12.15 Million |
+74.45% |
| 2024-03-31 | Rs643.88 Million ≈ $6.96 Million |
-6.60% |
| 2023-03-31 | Rs689.41 Million ≈ $7.46 Million |
-0.88% |
| 2022-03-31 | Rs695.55 Million ≈ $7.52 Million |
-5.62% |
| 2021-03-31 | Rs736.97 Million ≈ $7.97 Million |
+229.59% |
| 2020-03-31 | Rs223.60 Million ≈ $2.42 Million |
+9.03% |
| 2019-03-31 | Rs205.07 Million ≈ $2.22 Million |
+37.49% |
| 2018-03-31 | Rs149.16 Million ≈ $1.61 Million |
+27.56% |
| 2017-03-31 | Rs116.93 Million ≈ $1.26 Million |
+46.30% |
| 2016-03-31 | Rs79.93 Million ≈ $864.39K |
+16.62% |
| 2015-03-31 | Rs68.54 Million ≈ $741.22K |
-22.47% |
| 2014-03-31 | Rs88.41 Million ≈ $956.10K |
-50.37% |
| 2013-03-31 | Rs178.13 Million ≈ $1.93 Million |
-70.94% |
| 2012-03-31 | Rs612.90 Million ≈ $6.63 Million |
-18.67% |
| 2011-03-31 | Rs753.59 Million ≈ $8.15 Million |
+17.44% |
| 2010-03-31 | Rs641.68 Million ≈ $6.94 Million |
-18.13% |
| 2009-03-31 | Rs783.76 Million ≈ $8.48 Million |
-2.24% |
| 2008-03-31 | Rs801.74 Million ≈ $8.67 Million |
+41.26% |
| 2007-03-31 | Rs567.56 Million ≈ $6.14 Million |
+74.10% |
| 2006-03-31 | Rs326.00 Million ≈ $3.53 Million |
-- |
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more